NCT07501117招募中1 期
Neoadjuvant Ipilimumab and Nivolumab for Patients With High-risk Uveal Melanoma
Inge Marie Svane1 个研究点 分布在 1 个国家目标入组 15 人开始时间: 2026年6月29日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 15
- 试验地点
- 1
- 主要终点
- Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs)
研究概览
简要总结
The goal of this clinical trial is to investigate the safety and feasibility of neoadjuvant immunotherapy for patients with high-risk uveal melanoma. The main question is:
- Is neoadjuvant treatment with nivolumab and ipilimumab safe and feasible for patientt with high-riks uveal melanoma? In addition pathological response, distant metastases-free survival, overall survival and immunological changes in the tumor microenviroenment after therapy will be assesed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 ≤ 80
- •The patient is able to read and understand Danish.
- •Primary, localized and treatment-naive uveal melanoma planned for enucleation (high risk/T3-T4) and available for transvitreal biopsies. The initial diagnosis of uveal melanoma is based on ophthalmologic and clinical findings.
- •ECOG performance status of 0 or 1 (appendix 2)
- •The patient meets the following haematological and biochemical criteria at time of screening: a) AST and ALT ≤2,5 X ULN, b) Serum total bilirubin ≤1,5 X ULN or direct bilirubin ≤ ULN for patient with total bilirubin level > 1,5 ULN, c) Serum creatinine ≤1,5 X ULN, d) ANC (Absolute Neutrophil Count) ≥1,000/mcL, e) Platelets ≥ 75,000 /mcL, f) Hemoglobin ≥ 9 g/dL or ≥ 5.6 mmol/L
- •Signed statement of consent after receiving oral and written study information
- •Willingness to participate in the planned treatment and follow-up schedule
- •For women of childbearing potential (WOCBP) a negative serum pregnancy test at time of screening and the use of highly effective contraception is required. This applies from screening and until 6 months after treatment.
- •The following is considered highly effective methods of contraception:
- •Combined (estrogen and progestogen containing) hormonal contraception (oral, intravaginal or transdermal),
- •Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable)
- •Intrauterine device (IUD)
- •intrauterine hormone-releasing system (IUS)
- •Bilateral tubal occlusion,
- •Vasectomised partner provided that the vasectomy is confirmed successful,
- •Sexual abstinence defined as refraining from heterosexual intercourse. WOCBP must also agree to refrain from egg donation, storage, or banking during these same time periods.
- •- Men with female partner of childbearing potential must:
- •Use a condom during sexual intercourse from screening and until 6 months after treatment.
- •Ensure that their partner uses a highly effective method of contraception (as described above)
- •Agree to refrain from sperm donation, storage, or banking
排除标准
- •A history of prior malignancies. Patients treated for another malignancy can participate if they are without signs of disease for a minimum of 2 years after treatment. Subjects with curatively treated ductal carcinoma in situ (DCIS or LCIS) breast cancer for which they are taking hormonal therapy is acceptable. Resectable squamous or basal cell carcinoma of the skin is acceptable.
- •Requirement for immunosuppressive doses of systemic corticosteroids (>10 mg/day prednisone or equivalent) or other immunosuppressive drugs within the last 3 weeks prior to screening
- •The patient has any condition that will interfere with patient compliance or safety (including but not limited to psychiatric or substance abuse disorders)
- •The patient is pregnant or breastfeeding
- •The patient has an active infection requiring systemic therapy
- •Significant medical disorder according to investigator; e.g severe asthma or chronic obstructive lung disease, dysregulated heart disease or dysregulated diabetes mellitus.
- •Concurrent treatment with other experimental drugs
- •Any significant active autoimmune disease
- •Severe allergy or anaphylactic reactions earlier in life
- •Known hypersensitivity to one of the active drugs or one or more of the excipients.
结局指标
主要结局
Number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs)
时间窗: Until 6 months post treatment
Safety is evaluated by the Common Terminology Criteria (CTCAE) for Adverse Events version 6.0 and include the number of patients experiencing CTCAE grade ≥ 3 AEs and the occurrence of any treatment related adverse event (AEs) until 6 months post treatment.
Proportion of patients who complete the treatment regimen
时间窗: Until 6 months post treatment
Feasibility is evaluated as the proportion of patients who complete the treatment regimen defined as receiving at least one dose of both nivolumab and ipilimumab, followed by enucleation
次要结局
- Pathological response rate(through study completion, an average of 3 years)
- Objective response(through study completion, an average of 3 years)
- Distant metastases free survival (DMFS)(Until 6 months post treatment)
- Overall survival (OS)(Until 6 months post treatment)
研究者
Inge Marie Svane
Professor, MD
Herlev Hospital
研究点 (1)
Loading locations...
相似试验
招募中
1 期
Neoadjuvant nivolumab and ipilimumab for patients with high-risk uveal melanoma2025-524953-15-00Region Hovedstaden15
招募中
1 期
Neoadjuvant Immunotherapy Combined With Chemotherapy Sequenced With Endoscopic Resection for Esophageal Cancer (Endosurgery-02)NCT07317609Shanghai Zhongshan Hospital60
尚未招募
2 期
Neoadjuvant Iparomlimab and Tuvonralimab (QL1706) in Patients With Hormone Receptor Positive, HER2-negative Breast CancerHR-positive/HER2-negative Breast CancerNCT07396324RenJi Hospital55
已完成
2 期
A Study of Nivolumab and Nivolumab Combinations in Recurrent and Metastatic Colon Cancer2024-516004-42-01Bristol Myers Squibb International Corporation143
招募中
2 期
Tuvonralimab and Iparomlimab Based Regimens for the Neoadjuvant Treatment of Biliary Tract CancerNCT07267078Peking Union Medical College Hospital45